FI3839544T3 - Glycan nmr-mittaukset sepelvaltimotaudin riskin määrittämiseksi - Google Patents

Glycan nmr-mittaukset sepelvaltimotaudin riskin määrittämiseksi Download PDF

Info

Publication number
FI3839544T3
FI3839544T3 FIEP20199970.3T FI20199970T FI3839544T3 FI 3839544 T3 FI3839544 T3 FI 3839544T3 FI 20199970 T FI20199970 T FI 20199970T FI 3839544 T3 FI3839544 T3 FI 3839544T3
Authority
FI
Finland
Prior art keywords
glyca
nmr
risk
components
density lipoprotein
Prior art date
Application number
FIEP20199970.3T
Other languages
English (en)
Finnish (fi)
Inventor
James D Otvos
Irina Y Shalaurova
Dennis W Bennett
Justyna E Wolak-Dinsmore
Original Assignee
Liposcience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposcience Inc filed Critical Liposcience Inc
Application granted granted Critical
Publication of FI3839544T3 publication Critical patent/FI3839544T3/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0044—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4625—Processing of acquired signals, e.g. elimination of phase errors, baseline fitting, chemometric analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2576/00—Medical imaging apparatus involving image processing or analysis
    • A61B2576/02—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part
    • A61B2576/023—Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part for the heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Signal Processing (AREA)
  • Physiology (AREA)
  • Artificial Intelligence (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Urology & Nephrology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Cardiology (AREA)
FIEP20199970.3T 2012-06-08 2013-05-30 Glycan nmr-mittaukset sepelvaltimotaudin riskin määrittämiseksi FI3839544T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261657315P 2012-06-08 2012-06-08
US201261711471P 2012-10-09 2012-10-09
US201261739305P 2012-12-19 2012-12-19
US13/830,199 US9470771B2 (en) 2012-06-08 2013-03-14 NMR measurements of NMR biomarker GlycA

Publications (1)

Publication Number Publication Date
FI3839544T3 true FI3839544T3 (fi) 2024-12-27

Family

ID=49712504

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20199970.3T FI3839544T3 (fi) 2012-06-08 2013-05-30 Glycan nmr-mittaukset sepelvaltimotaudin riskin määrittämiseksi

Country Status (9)

Country Link
US (3) US9470771B2 (https=)
EP (3) EP3839544B1 (https=)
JP (1) JP6177899B2 (https=)
CN (1) CN104508471B (https=)
AU (1) AU2013272014B2 (https=)
CA (2) CA2874550C (https=)
FI (1) FI3839544T3 (https=)
SG (1) SG11201407803TA (https=)
WO (1) WO2013184483A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9076342B2 (en) 2008-02-19 2015-07-07 Architecture Technology Corporation Automated execution and evaluation of network-based training exercises
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US20140358451A1 (en) * 2013-06-04 2014-12-04 Arizona Board Of Regents On Behalf Of Arizona State University Fractional Abundance Estimation from Electrospray Ionization Time-of-Flight Mass Spectrum
PT3074775T (pt) * 2013-11-27 2018-10-31 Inst Dinvestigacio Sanitaria Pere Virgili Método para a caracterização de lipoproteínas
CA2931648C (en) * 2014-01-06 2022-11-29 Liposcience, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9952232B2 (en) * 2014-09-11 2018-04-24 Liposcience, Inc. Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter
EP3197045B1 (en) * 2014-10-31 2018-09-19 Huawei Technologies Co., Ltd. Curve fitting circuit, analog predistorter and radio frequency signal transmitter
US10083624B2 (en) 2015-07-28 2018-09-25 Architecture Technology Corporation Real-time monitoring of network-based training exercises
US10803766B1 (en) 2015-07-28 2020-10-13 Architecture Technology Corporation Modular training of network-based training exercises
EP3258285B1 (en) * 2016-06-14 2020-10-21 Bruker BioSpin GmbH Method for predicting chemical shift values of nmr spin systems in a sample of a fluid class, in particular in a sample of a biofluid
DE102016224691A1 (de) * 2016-12-12 2018-06-14 Numares Ag Verfahren zur Analyse eines NMR-Spektrums einer lipoproteinhaltigen Probe
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
CA3073827C (en) * 2017-09-07 2023-10-17 Liposcience, Inc. Multi-parameter metabolic vulnerability index evaluations
CN107796946B (zh) * 2017-10-20 2019-10-25 中国医学科学院基础医学研究所 尿液中冠心病的蛋白标志物及其用途
US11467171B2 (en) * 2017-11-10 2022-10-11 Liposcience, Inc. Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopy
US20200367795A1 (en) * 2018-01-18 2020-11-26 New York University System and method for blood glucose monitoring using magnetic resonance spectroscopy
CN109805898B (zh) * 2019-03-22 2024-04-05 中国科学院重庆绿色智能技术研究院 基于注意力机制时序卷积网络算法的危重症死亡预测方法
US11887505B1 (en) 2019-04-24 2024-01-30 Architecture Technology Corporation System for deploying and monitoring network-based training exercises
CN116848409A (zh) * 2021-01-22 2023-10-03 布鲁克碧奥斯平有限公司 使用扩散和弛豫编辑的质子nmr谱的感染诊断和表征
EP4281768A1 (en) * 2021-01-22 2023-11-29 Bruker BioSpin MRI GmbH Infection diagnosis and characterization using diffusion and relaxation edited proton nmr spectroscopy
FI130189B (fi) * 2021-02-19 2023-04-03 Nightingale Health Oyj Menetelmä sappirakon häiriön kehittymisriskin määrittämiseksi kohteelle
AU2023320157A1 (en) * 2022-08-05 2025-01-30 Liposcience, Inc. Metabolic vulnerability analyzed by nmr
DE102023110285B3 (de) 2023-04-21 2024-05-08 Universität zu Lübeck, Körperschaft des öffentlichen Rechts Nmr-messung von glykoproteinen

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529710A (en) 1981-06-12 1985-07-16 The United States Of America As Represented By The United States Department Of Energy Method of using a nuclear magnetic resonance spectroscopy standard
JPH0698036B2 (ja) 1986-10-20 1994-12-07 小野薬品工業株式会社 アミノ酸の選択的定量法
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
US6653140B2 (en) * 1999-02-26 2003-11-25 Liposcience, Inc. Methods for providing personalized lipoprotein-based risk assessments
WO2000051054A1 (en) 1999-02-26 2000-08-31 Lipomed, Inc. Methods, systems, and computer program products for analyzing and presenting risk assessment results based on nmr lipoprotein analysis of blood
EP1171778B1 (en) 1999-04-22 2006-03-01 Liposcience, Inc. Nmr-method for determining the risk of developing type 2 diabetes
CA2331116A1 (en) 2001-01-15 2002-07-15 Chenomx, Inc. Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system
WO2003012416A1 (en) 2001-08-01 2003-02-13 Liposcience, Inc. Method of determining presence and concentration of lipoprotein x in blood plasma and serum
AU2003232406A1 (en) 2002-06-14 2003-12-31 Pfizer Inc. Metabolic phenotyping
WO2004040407A2 (en) 2002-10-25 2004-05-13 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
WO2004085996A2 (en) 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
CA2542107A1 (en) 2003-10-23 2005-05-12 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using mathematical models that consider in vivo concentration gradients of ldl particle subclasses of discrete size
WO2005098463A2 (en) 2004-04-01 2005-10-20 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
WO2006057081A1 (en) 2004-11-24 2006-06-01 Mitsuyo Okazaki Method for analyzing lipoproteins
JP5006524B2 (ja) 2005-05-13 2012-08-22 株式会社日立製作所 緩和時間特定のためのｎｍｒ装置の信号処理方法
JP4358814B2 (ja) 2005-11-09 2009-11-04 花王株式会社 試料の解析方法
EP2339346B1 (en) 2006-03-24 2014-09-03 Metanomics GmbH Methods for predicting diabetes type II
WO2007133593A2 (en) 2006-05-10 2007-11-22 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements
WO2008137075A2 (en) 2007-05-02 2008-11-13 President And Fellows Of Harvard College Compositions and methods for the treatment of metabolic disorders and inflammation
US7923257B2 (en) 2007-05-04 2011-04-12 Perkinelmer Health Sciences, Inc. Detecting isomers using differential derivatization mass spectrometry
EP2019311A1 (en) 2007-07-23 2009-01-28 F.Hoffmann-La Roche Ag A method for detecting a target substance by nuclear magnetic resonance
WO2010005982A2 (en) 2008-07-07 2010-01-14 The General Hospital Corporation Multiplexed biomarkers of insulin resistance
KR20110086074A (ko) 2008-10-20 2011-07-27 리포사이언스, 인크. 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램
US20120122981A1 (en) 2009-03-31 2012-05-17 Yun Fu Hu Biomarkers Related to Insulin Resistance and Methods using the Same
US8741788B2 (en) 2009-08-06 2014-06-03 Applied Materials, Inc. Formation of silicon oxide using non-carbon flowable CVD processes
US7935643B2 (en) 2009-08-06 2011-05-03 Applied Materials, Inc. Stress management for tensile films
US8449942B2 (en) 2009-11-12 2013-05-28 Applied Materials, Inc. Methods of curing non-carbon flowable CVD films
US20110136241A1 (en) 2009-12-08 2011-06-09 Stephen Naylor Type ii diabetes molecular bioprofile and method and system of using the same
JP2013517616A (ja) 2010-01-06 2013-05-16 アプライド マテリアルズ インコーポレイテッド 酸化物ライナを使用する流動可能な誘電体
AU2011256064B2 (en) 2010-05-21 2016-09-15 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
WO2014059025A1 (en) 2012-10-09 2014-04-17 Liposcience, Inc. Nmr quantification of branched chain amino acids

Also Published As

Publication number Publication date
US20210080452A1 (en) 2021-03-18
SG11201407803TA (en) 2014-12-30
EP3839544A1 (en) 2021-06-23
HK1207156A1 (en) 2016-01-22
EP3839544B1 (en) 2024-10-02
US9470771B2 (en) 2016-10-18
JP6177899B2 (ja) 2017-08-09
AU2013272014B2 (en) 2017-05-25
CN104508471A (zh) 2015-04-08
EP4439587A2 (en) 2024-10-02
US20170003269A1 (en) 2017-01-05
WO2013184483A1 (en) 2013-12-12
EP2859339B1 (en) 2020-10-28
EP4439587A3 (en) 2024-12-18
EP2859339A4 (en) 2016-08-03
CA2874550C (en) 2022-04-19
CA2874550A1 (en) 2013-12-12
US20130328561A1 (en) 2013-12-12
JP2015522806A (ja) 2015-08-06
US10852293B2 (en) 2020-12-01
CN104508471B (zh) 2017-09-19
US11692995B2 (en) 2023-07-04
CA3146947A1 (en) 2013-12-12
EP2859339A1 (en) 2015-04-15
AU2013272014A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
FI3839544T3 (fi) Glycan nmr-mittaukset sepelvaltimotaudin riskin määrittämiseksi
US20240096497A1 (en) Multi-Parameter Diabetes Risk Evaluations
Eilers et al. Baseline correction with asymmetric least squares smoothing
Griffin et al. iTRAQ reagent-based quantitative proteomic analysis on a linear ion trap mass spectrometer
Luo et al. Metabolomic analysis of the plasma of patients with high-altitude pulmonary edema (HAPE) using 1H NMR
JP2015522806A5 (https=)
Kuligowski et al. Analysis of multi-source metabolomic data using joint and individual variation explained (JIVE)
CA2887475C (en) Nmr quantification of branched chain amino acids
NZ703875A (en) Spectroscopic analysis
Simcoe The carbon content of intergalactic gas at z= 4.25 and its evolution toward z= 2.4
JP6814732B2 (ja) Ｈｄｌおよび炎症性バイオマーカインタラクションパラメータを含むリスクパラメータを用いた心血管リスク評価
Mosconi et al. Different quantification algorithms may lead to different results: a comparison using proton MRS lipid signals
Zhang et al. FlavonQ: an automated data processing tool for profiling flavone and flavonol glycosides with ultra-high-performance liquid chromatography–diode array detection–high resolution accurate mass–mass spectrometry
Benahmed et al. NMR HRMAS spectroscopy of lung biopsy samples: comparison study between human, pig, rat, and mouse metabolomics
US20110004453A1 (en) Method for prediction of lipoprotein content from nmr data
Tharaud et al. uFREASI: user-FRiendly Elemental dAta procesSIng. A free and easy-to-use tool for elemental data treatment
Rienda et al. Comparing the direct assessment of steatosis in liver explants with mid-and near-infrared vibrational spectroscopy, prior to organ transplantation
EP2515097A3 (en) Spectrometric device
JP6533749B2 (ja) 質量分析装置及び質量分析方法
Zhao et al. Rapid determination of phytic acid content in cottonseed meal via near infrared spectroscopy
Gupta et al. Beyond the limit of assignment of metabolites using minimal serum samples and 1H NMR spectroscopy with cross-validation by mass spectrometry
US10488329B2 (en) Calibration apparatus, calibration curve creation method, and independent component analysis method
Laubscher et al. Determination of potential absorbance bands of fumonisin B1 in methanol with near infrared spectroscopy
Koh et al. An approach to automated frequency-domain feature extraction in nuclear magnetic resonance spectroscopy
Craven et al. Comparison of seven modelling algorithms for GABA-edited 1H-MRS: evaluation of data from 20 sites, with: FSL-MRS, Gannet, jMRUI (AMARES, QUEST), LCModel, Osprey and Tarquin